[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339978-105":59,"doc-detail-339978-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-analysis-of-multi-omics-data-to-identify-deregulated-molecular-pathways-and-druggable-targets-in-chronic-lymphocytic-leukemia-study","Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia - Study","","Chronic Lymphocytic Leukemia (CLL) is the most common B-cell malignancy in the Western world, marked by frequent relapses after temporary remissions. The study integrates public proteomic, transcriptomic, and patient survival datasets to compare healthy versus CLL samples, revealing ~1000 differentiating proteins, including 608 upregulated and 415 downregulated proteins. Upregulated candidates such as YEATS2, PIGR, and SNRPA are proposed as prognostic biomarkers. Pathway analysis highlights RNA processing, stress resistance, and immune response deficits. Drug repurposing candidates include Bosutinib, Vorinostat, and Panobinostat, with limited transcriptome-proteome correlation emphasizing post-transcriptional regulation. The findings support integrative omics for identifying deregulated pathways and therapeutic directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-analysis-of-multi-omics-data-to-identify-deregulated-molecular-pathways-and-druggable-targets-in-chronic-lymphocytic-leukemia-study/339978/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-analysis-of-multi-omics-data-to-identify-deregulated-molecular-pathways-and-druggable-targets-in-chronic-lymphocytic-leukemia-study/339978.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How did the study compare healthy and CLL samples?","Question",{"text":112,"@type":113},"It integrated publicly available proteomic, transcriptomic, and patient survival datasets to identify differences between healthy and CLL samples.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What types of proteins and potential biomarkers were found in CLL?",{"text":117,"@type":113},"Approximately 1000 proteins differentiated the groups, with 608 upregulated and 415 downregulated in CLL. Upregulated proteins such as YEATS2, PIGR, and SNRPA were highlighted as potential prognostic biomarkers.",{"name":119,"@type":110,"acceptedAnswer":120},"Which pathways and drugs were implicated for CLL progression and repurposing?",{"text":121,"@type":113},"Key pathways included RNA processing, stress resistance, and immune response deficits. The study identified Bosutinib, Vorinostat, and Panobinostat as existing drugs for further investigation in CLL drug repurposing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339978,1790156190,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nIntegrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia  \nDimitra Mavridou 1,2,3, Konstantina Psatha 2,3,4 and Michalis Aivaliotis 1,2,3, *  \nCitation: Mavridou, D.; Psatha, K.; Aivaliotis, M. Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia. J. Pers. Med. 2024, 14, 831. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/jpm14080831](10.3390/jpm14080831)  \nAcademic Editors: Panagiota Filippou and Anastasia Constantinidou  \nReceived: 25 June 2024  \nRevised: 25 July 2024  \nAccepted: 27 July 2024  \nPublished: 6 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Laboratory of Biological Chemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece; [dimitramd@auth.gr](dimitramd@auth.gr)  \n2 Functional Proteomics and Systems Biology (FunPATh), Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece; [kpsatha@auth.gr](kpsatha@auth.gr)  \n3 Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece  \n4 Laboratory of Medical Biology—Genetics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece  \n* Correspondence: [aivaliotis@auth.gr](aivaliotis@auth.gr)  \nAbstract: Chronic Lymphocytic Leukemia (CLL) is the most common B-cell malignancy in the Western world, characterized by frequent relapses despite temporary remissions. Our study integrated publicly available proteomic, transcriptomic, and patient survival datasets to identify key differences between healthy and CLL samples. We exposed approximately 1000 proteins that differentiate healthy from cancerous cells, with 608 upregulated and 415 downregulated in CLL cases. Notable upregulated proteins include YEATS2 (an epigenetic regulator), PIGR (Polymeric immunoglobulin receptor), and SNRPA (a splicing factor), which may serve as prognostic biomarkers for this disease. Key pathways implicated in CLL progression involve RNA processing, stress resistance, and immune response deficits. Furthermore, we identified three existing drugs—Bosutinib, Vorinostat, and Panobinostat—for potential further investigation in drug repurposing in CLL. We also found limited correlation between transcriptomic and proteomic data, emphasizing the importance of proteomicsin understanding gene expression regulation mechanisms. This generally known disparity highlights once again that mRNA levels do not accurately predict protein abundance due to many regulatory factors, such as protein degradation, post-transcriptional modifications, and differing rates of translation. These results demonstrate the value of integrating omics data to uncover deregulated proteins and pathways in cancer and suggest new therapeutic avenues for CLL.  \nKeywords: chronic lymphocytic leukemia; lymphoma; proteomics; transcriptomics; drug repurposing; personalized medicine  \n1. Introduction  \nChronic Lymphocytic Leukemia (CLL) is a blood malignancy marked by the progressive clonal proliferation of B-cell-like cells in the blood, bone marrow, and secondary lymphoid tissues [1–3] . Despite advancements in research, significant progress in disease prognosis and the development of therapeutic strategies addressing the diverse genetic profiles and clinical outcomes of CLL remains elusive [4–6] . Although patients often initially respond well to treat","cbCaieL4UZml947p","https://ap.wps.com/l/cbCaieL4UZml947p","pdf",7250336,26,"English","# Abstract\n# Introduction\n## Disease background and unmet needs\n## Genetic and molecular classification\n## Pathogenesis complexity","[{\"question\":\"How did the study compare healthy and CLL samples?\",\"answer\":\"It integrated publicly available proteomic, transcriptomic, and patient survival datasets to identify differences between healthy and CLL samples.\"},{\"question\":\"What types of proteins and potential biomarkers were found in CLL?\",\"answer\":\"Approximately 1000 proteins differentiated the groups, with 608 upregulated and 415 downregulated in CLL. Upregulated proteins such as YEATS2, PIGR, and SNRPA were highlighted as potential prognostic biomarkers.\"},{\"question\":\"Which pathways and drugs were implicated for CLL progression and repurposing?\",\"answer\":\"Key pathways included RNA processing, stress resistance, and immune response deficits. The study identified Bosutinib, Vorinostat, and Panobinostat as existing drugs for further investigation in CLL drug repurposing.\"}]","Integrative Analysis of Multi-Omics Data to Identify Deregulated Molecular Pathways and Druggable Targets in Chronic Lymphocytic Leukemia - Study | PDF",1790033461,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dac6e8f36892a9bcdfe812b2e1351bc.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d3b0482d350ca48c656ee59912cc7317.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a30d380680b7aae401436cbda1de6ce.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f75460942d8fa654e6293d92350e93f3.webp",980,1385]